Agilent Ventures, the venture capital arm of Agilent Technologies, focused on investing in early-stage high-technology companies globally, with a particular emphasis on life sciences, wireless, and wireline/optical communications. The strategy involved injecting $2 million to $10 million into each venture, with plans to invest up to $100 million annually, and offering startups access to Agilent's technological resources and partnership opportunities. However, Agilent Ventures is no longer actively investing.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (50% of deals). Average disclosed round size is $37.4M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Biofidelity | Series A | $24M | Apr 2024 |
 Molecular Assemblies Inc. | Series B | $25.8M | Mar 2022 |
 Akadeum Life Sciences, Inc. | Series B | $17.5M | Oct 2021 |
 RareCyte | Series B | $24M | Sep 2021 |
 MOBILion Systems Inc. | Series C | $60M | Jul 2021 |
 DNA Script | Series B | $75.5M | Aug 2020 |
| Molecular Assemblies Inc. | Seed | $2.3M | Dec 2016 |
 Mission Bio | Series C | $70M | — |
Top Co-Investors
Last updated: 15 April 2026